With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. | First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma Preliminary results of safety durable survival and immune biomarkers